Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: The I-MOVE multicentre case-control study, influenza season 2012/13

Eurosurveillance

Volumn 19, Issue 6, 2014, Pages

  Kissling, E ^a   Valenciano, M ^a   Buchholz, U ^b   Larrauri, A ^c   Cohen, J M ^d   Nunes, B ^e   Rogalska, J ^f   Pitigoi, D ^g,h   Paradowska Stankiewicz, I ⁱ   Reuss, A ^b   Jimenez Jorge S ^c   Daviaud, I ^d   Guiomar, R ^e   O'Donnell, J ^f   Necula, G ^j   Gluchowska M ⁱ   Moren, A ^a  

^a EPICONCEPT   (France)

^b ROBERT KOCH INSTITUTE   (Germany)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d GROG/Open Rome   (France)

^e NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^f HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^g CANTACUZINO INSTITUTE   (Romania)

^h CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ NATIONAL MEDICINES INSTITUTE   (Poland)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EUROPE; EUROPEAN UNION; FEMALE; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PREGNANCY; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROAT CULTURE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EUROPE; EUROPEAN UNION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANDEMICS; POPULATION SURVEILLANCE; SEASONS; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 84896709186     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.6.20701     Document Type: Article

References (29)

1. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Stockholm: ECDC; Jul 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-July-2013.pdf
2. World Health Organisation (WHO). Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Geneva: WHO; Feb 2012. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf
3. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. I-MOVE towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill. 2009;14(44):pii: 19388.
4. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5):pii: 20390.
5. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS ONE 6(11): e27622.
6. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388. http://dx.doi.org/10.1371/journal.pmed.1000388
7. Valenciano M, Kissling E; I-MOVE Case-Control Study Team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012-3. Euro Surveill. 2013;18(7):pii=20400.
8. European Commission. Commission Decision 2009/363/EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Union. Luxembourg: Publications Office of the European Union. 1.5.2009: L 110/58. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF
9. European Centre for Disease Prevention and Control (ECDC). Laboratory surveillance of influenza. Laboratory surveillance of influenza. Stockholm: ECDC. [Accessed 14 Aug 2013]. Available from: http://www.ecdc.europa.eu/en/activities/surveillance/EISN/laboratory_network/Pages/laboratory_surveillance_influenza.aspx
10. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206. http://dx.doi.org/10.1037/1082-989X.11.2.193
11. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. P. 568. http://dx.doi.org/10.1007/978-1-4757-3462-1
12. Bragstad K, Emborg H, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012-3--a rapid epidemiological and virological assessment. Euro Surveill. 2013;18(6):pii: 20397.
13. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013;62(7):119-23.
14. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010;28(46):7381-8. http://dx.doi.org/10.1016/j.vaccine.2010.09.010
15. Stukel TA, Demidenko E, Dykes J, Karagas MR. Two-stage methods for the analysis of pooled data. Stat Med. 2001;20(14):2115-30. http://dx.doi.org/10.1002/sim.852
16. Cheng AC, Kotsimbos T, Kelly HA, Irving LB, Bowler SD, Brown SG, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine. 2011;29(43):7320-5. http://dx.doi.org/10.1016/j.vaccine.2011.07.087
17. Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutélaers B, et al. Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls. BMC Infect Dis. 2012;12:127. http://dx.doi.org/10.1186/1471-2334-12-127
18. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011;29(38):6558-63. http://dx.doi.org/10.1016/j.vaccine.2011.07.002
19. Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis. 2011;203(1):32-9. http://dx.doi.org/10.1093/infdis/jiq014
20. Cowling BJ, Nishiura H. Virus interference and estimates of influenza vaccine effectiveness from test-negative studies. Epidemiology. 2012;23(6):930-1. http://dx.doi.org/10.1097/EDE.0b013e31826b300e
21. Sundaram ME, McClure DL, Vanwormer JJ, Friedrich TC, Meece JK, Belongia EA. Influenza Vaccination is Not Associated with Detection of Non-Influenza Respiratory Viruses in Seasonal Studies of Influenza Vaccine Effectiveness. Clin Infect Dis. 2013;57(6):789-93. http://dx.doi.org/10.1093/cid/cit379
22. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104-9. http://dx.doi.org/10.1016/j.vaccine.2013.04.026
23. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill. 2013;18(37):pii: 20585.
24. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8. http://dx.doi.org/10.1016/j.vaccine.2013.02s053
25. World Health Organisation (WHO). Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season. Geneva: WHO; 2013. [Accessed 15 Aug 2013]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/index.html
26. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, Mahmud SM, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):pii: 20394.
27. Centers for Disease Control and Prevention (CDC). Early estimates of seasonal influenza vaccine effectiveness--United States, January 2013. MMWR Morb Mortal Wkly Rep. 2013;62(2):32-5. s
28. Castilla J, Martinez-Baz I, Martinez-Artola V, Fernandez-Alonso M, Reina G, Guevara M, et al. Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis. Euro Surveill. 2013;18(7):pii=20404.
29. McMenamin J, Andrews N, Robertson C, Fleming D, Durnall H, von Wissmann B, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill. 2013;18(5):pii: 20393.